AM Study Update: March 16, 2026

Evidence Watch  |  Nature medicine (2025)

Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.

# Study Finding Summary This phase 3 trial evaluated a full-spectrum cannabis extract (DKJ127) for chronic low back pain, addressing a treatment gap where current pharmacologic options show limited efficacy and safety concerns.

Evidence Watch  |  Acta paediatrica (Oslo, Norway : 1992) (2025)

Cannabinoids for Medical Purposes in Children: A Living Systematic Review.

# Study Summary This living systematic review continuously evaluates safety and efficacy data of medical cannabinoids in pediatric populations, providing clinicians with updated evidence on cannabinoid use in children.

Evidence Watch  |  British journal of sports medicine (2026)

Influences on the mental health and well-being of retired professional athletes from high contact team sports: a mixed methods systematic review.

# Study Summary for Cannabis Clinicians This systematic review examines mental health prevalence and influencing factors in retired professional high-contact team sport athletes, providing evidence on psychiatric symptom patterns relevant to understanding substance use risk in this population.

Evidence Watch  |  Journal of medical Internet research (2024)

Effectiveness of the Minder Mobile Mental Health and Substance Use Intervention for University Students: Randomized Controlled Trial.

# Study Summary for Cannabis Clinicians The Minder mobile intervention shows promise for addressing substance use and mental health challenges in university students, a population at risk for cannabis use disorders during this developmental transition period.

Evidence Watch  |  Journal of anxiety disorders (2024)

Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.

# Study Summary for Cannabis Clinicians **Unable to provide:** The abstract is incomplete and lacks results/findings. A complete abstract with outcomes is needed to accurately describe the study’s finding and clinical relevance.

Evidence Watch  |  BMJ open (2026)

Research on Eating and Adolescent Lifestyle (REAL) 2.0: 15-year follow-up study of eating disorders and weight-related trajectories, mental health and substance use health from early adolescence to early adulthood-a Canadian cohort profile.

# REAL 2.0 Study – Cannabis Relevance The study tracks adolescent psychosocial risk factors and their association with substance use trajectories into adulthood, providing evidence on developmental pathways relevant to cannabis initiation and use patterns in Canadian youth.

Evidence Watch  |  Annals of the rheumatic diseases (2026)

Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.

# Study Summary This randomized controlled trial evaluated cannabidiol’s efficacy and safety versus placebo for fibromyalgia pain, providing evidence clinicians need to assess CBD’s therapeutic value in this patient population.

Evidence Watch  |  International journal of environmental research and public health (2026)

Therapeutically Motivated Cannabis Use for Anxiety: Daily and Longitudinal Reductions Vary Between Flower and Edible Products.

# Study Finding Summary Cannabis flower and edible products showed differential effects on anxiety reduction, with daily use patterns and longitudinal outcomes varying between product types—information relevant for clinicians personalizing cannabis recommendations for anxiety management.

Evidence Watch  |  Journal of sleep research (2026)

Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.

# Study Summary for Cannabis Clinicians This pilot trial examined how single oral doses of THC and CBD affect sleep architecture and daytime function using high-density EEG, addressing gaps in understanding cannabinoid effects on sleep quality.

Evidence Watch  |  Clinical pharmacology and therapeutics (2026)

Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.

CBD demonstrated no direct effect on cortical excitability in this controlled trial, suggesting its anti-seizure efficacy may depend on drug interactions rather than direct neuronal modulation.

Evidence Watch  |  Journal of psychiatric research (2025)

Pre-trauma insomnia and posttraumatic alcohol and cannabis use in the AURORA observational cohort study of trauma survivors.

# Study Finding Summary Pre-trauma insomnia predicted increased posttraumatic cannabis use in trauma survivors, suggesting cannabis clinicians should assess baseline sleep disturbance when evaluating substance use risk in traumatized patients.

Evidence Watch  |  JAMA health forum (2026)

Adolescent Cannabis Use and Risk of Psychotic, Bipolar, Depressive, and Anxiety Disorders.

# Study Summary Adolescent cannabis use is associated with increased risk of psychotic, bipolar, depressive, and anxiety disorders—a finding clinicians should consider when screening and counseling young patients about cannabis exposure and mental health vulnerability.

Evidence Watch  |  Drug and alcohol dependence (2016)

Anxiety, depression and risk of cannabis use: Examining the internalising pathway to use among Chilean adolescents.

# Study Finding Summary Adolescents experiencing depression and anxiety symptoms may use cannabis as a coping mechanism, suggesting clinicians should screen for internalising disorders when assessing cannabis use risk in this population.

Evidence Watch  |  Journal of clinical pharmacology (2025)

Therapeutic Use of Cannabis Derivatives and Their Analogs for Autism Spectrum Disorder: A Systematic Review.

# Study Summary Cannabis derivatives showed promising therapeutic effects for autism spectrum disorder symptoms, providing evidence relevant to clinical applications in managing social interaction difficulties and behavioral patterns in autistic populations.

Evidence Watch  |  The Journal of clinical psychiatry (2024)

Maternal Cannabis Use in Pregnancy and Autism Spectrum Disorder or Attention-Deficit/Hyperactivity Disorder in Offspring.

# Study Finding and Clinical Relevance Maternal cannabis use during pregnancy was associated with increased risk of autism spectrum disorder and/or attention-deficit/hyperactivity disorder in offspring, warranting counseling on neurodevelopmental risks for pregnant cannabis users.

Evidence Watch  |  Cannabis and cannabinoid research (2026)

A Randomized, Open-Label Trial to Assess Feasibility and Tolerability of Topical Cannabis Balms for the Treatment of Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS).

# Study Summary This feasibility trial evaluates topical cannabis balms for treating AIMSS—musculoskeletal pain affecting approximately two-thirds of postmenopausal women taking aromatase inhibitors for breast cancer.

Evidence Watch  |  Psychiatry research. Neuroimaging (2026)

A single dose of cannabidiol modulates the relationship between hippocampal glutamate and learning-related prefrontal activation in individuals at Clinical High Risk of Psychosis.

# Study Finding Summary A single CBD dose modified the relationship between hippocampal glutamate levels and prefrontal brain activation during learning tasks in individuals at clinical high risk for psychosis, suggesting a potential neurobiological mechanism for CBD’s therapeutic effects.

Evidence Watch  |  Medicine and science in sports and exercise (2026)

Daily Use of a Broad-Spectrum Cannabidiol Supplement Produces Detectable Concentrations of Cannabinoids in Urine Prohibited by the World Anti-Doping Agency: An Effect Amplified by Exercise.

# Study Finding Summary Daily broad-spectrum CBD supplementation produces detectable urine levels of WADA-prohibited cannabinoids, with exercise amplifying this effect—relevant for clinicians counseling athletes on CBD product composition and drug testing risks.

Evidence Watch  |  Journal of neurodevelopmental disorders (2025)

Long-term safety and tolerability of transdermal cannabidiol gel in children and adolescents with Fragile X syndrome (ZYN2-CL-017): an interim analysis of an ongoing open-label extension study.

# Study Summary ZYN002, a transdermal cannabidiol gel, was evaluated for long-term safety and tolerability in children and adolescents with Fragile X syndrome, providing clinical data on cannabinoid treatment in pediatric neurodevelopmental disorders.

Evidence Watch  |  Complementary therapies in clinical practice (2025)

Challenges in conducting a feasibility randomized controlled trial of medicinal cannabis for endometriosis pain in Australia.

# Study Finding Summary This feasibility study evaluated the practical implementation, patient acceptance, and safety profile of medicinal cannabis interventions for endometriosis pain management, addressing a treatment gap between patient use and clinical evidence.